Beyond Air Reports Q2 FY2027 Revenue of $2.3 Million, Up 28% Year-Over-Year
Beyond Air reported record quarterly revenue of $2.3 million for the quarter ended September 30, 2026, representing approximately 28% year-over-year growth, driven by continued adoption of the first-generation LungFit PH system. The company reported a net loss attributable to common stockholders of $7.8 million, or a loss of $3.76 per basic and diluted share, compared with a net loss of $7.9 million, or a loss of $24.98 per basic and diluted share, for the same period last year. Beyond Air reaffirmed its revenue...
Forward guidance
Key takeaways
Revenue: Record quarterly revenue of $2.3 million, up 28% year-over-year and up 31% sequentially from Q1 FY2027.
EPS: Net loss of $3.76 per basic and diluted share, compared with a loss of $24.98 per share in the prior year period (prior period adjusted for 1-for-20 reverse stock split in July 2026).
Operating expenses: R&D decreased to $1.6 million from $2.5 million due to completion of second-generation LungFit PH development; SG&A decreased to $4.6 million from $4.9 million.
Other expense increased to $2.2 million from $0.6 million, driven by increased debt and interest expense plus a charge for scrapped materials.
Cash position: $18.5 million in cash, cash equivalents, restricted cash, and marketable securities as of September 30, 2026.
FDA status: PMA supplement for second-generation LungFit PH remains under FDA review; audit-readiness process expected to complete mid-December.
Strategic update: Announced definitive agreement for UNIVO Pharmaceutical Industries to acquire controlling interest in NeuroNOS Israel Ltd.
Key metrics
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open SEC filingFollow XAIR in real time
Get material earnings, filing, IR, and earnings-call alerts by email.